Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0034-1391495 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Appendiceal Neuroendocrine Tumor: Clinicopathologic Characteristics of Six Cases and Review of the Literature.
In Vivo
December 2024
Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea;
Background/aim: Appendiceal neuroendocrine tumors (ANETs) are the most prevalent type of appendiceal neoplasm and the fifth most common neuroendocrine tumor in the gastrointestinal tract. In this study, we described the clinicopathological features of patients with ANET.
Patients And Methods: We reviewed the clinicopathological findings and histopathological reports of six patients diagnosed with ANET between January 2014 and December 2023 at Korea University Medical Center, Anam Hospital.
Article Synopsis
- The diagnosis of malignant uterine PEComas can be difficult, with some cases linked to TSC gene mutations affecting treatment responses.
- A 52-year-old woman had a malignant PEComa identified after surgery for suspected fibroids, and despite initially declining additional treatment, she later underwent surgery for a recurrent tumor.
- Treatment with the mTOR inhibitor everolimus led to a positive outcome, with nearly 3 years of disease remission without signs of recurrence or progression.
Efficacy and safety of endoscopic subserosal dissection treatment for gastrointetinal submucosal tumors in the upper gastrointestinal tract.
BMC Surg
October 2024
Department of Gastroenterology and Hepatology, Binzhou Medical University Hospital, Binzhou, Shandong Province, China.
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of endoscopic subserosal dissection (ESSD) for treating upper gastrointestinal submucosal tumors, involving 16 patients from July 2018 to December 2021.
- Results showed that all patients had successful removal of tumors with no complications, achieving 100% en bloc and R0 resection rates, and tumors were primarily located in the corpus with an average size of 2.78 cm.
- Follow-up over 9 months indicated no recurrence or metastasis, suggesting that ESSD is a safe and effective option for curative treatment of these tumors in patients without metastasis.
Uterine Tumor Resembling Ovarian Sex-Cord Tumor (UTROSCT): A Rare Polyphenotypic Neoplasm.
Diagnostics (Basel)
June 2024
Department of Medicine and Surgery, Pathology Unit, University of Parma, Viale A. Gramsci, 14, 43126 Parma, Italy.
Uterine tumor resembling ovarian sex-cord tumor (UTROSCT) is a rare form of uterine mesenchymal neoplasm. Although UTROSCT generally exhibits benign behavior with a favorable prognosis, this neoplasm is nevertheless classified as being of uncertain malignant potential, given its low rate of recurrence and the fact that it rarely produces metastases (e.g.
View Article and Find Full Text PDFFIGO 2023 endometrial staging: a leap of faith into the new "prognostic based' rather than "anatomical based" staging-too fast too furious??
J Cancer Res Clin Oncol
May 2024
Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, Assam, India.
Background: In 2023 FIGO revised the endometrial cancer staging system after 13 years. There is a lacuna of data regarding the performance and practicality of the revised 2023 FIGO staging schema for endometrial cancer from Low Middle-Income Countries (LMIC).
Objective: To estimate the shift of stage and adjuvant management of endometrial cancer based on the FIGO 2023 system compared to the FIGO 2009 system and assess the predictive potential of the FIGO 2023 system.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!